Skip to main content

Advertisement

Table 1 Patient characteristics at baseline

From: Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial

  Active n = 30 Placebo n = 28 p value
Age (years) 68.1 ± 5.9 69.2 ± 6.3 0.35
Male/female ratio 12/18 11/17 0.45
Duration of rhinitis (years) 4.4 ± 1.4 6.9 ± 2.1 0.23
Number of subjects with asthma 0 0
Number of patients with eczema 2 1 0.21
Number of smokers 6 5 0.67
Number of patients with stable coronary disease 8 10 0.17
Number of patients with arterial hypertension 12 9 0.22
Number of patients with diabetes 4 5 0.39
Mean weekly nasal symptom score 3.21 ± 0.93 3.11 ± 0.54 0.18
Mean weekly non-nasal symptom score 3.64 ± 0.55 3.21 ± 0.9 0.11
Mean weekly medication score 0.45 ± 0.17 0.51 ± 0.09 0.59
Total IgE 187.43 ± 64.01 201.9 ± 83.22 0.19
Specific IgE to Der p (kU/l) 24.9 ± 10.11 27.31 ± 13.9 0.4
Specific IgE to Der f (kU/l) 17.45 ± 8.31 15.9 ± 10.5 0.19